En face swept-source optical coherence tomography (SS-OCT) and SS-OCT angiography findings of retinal astrocytic hamartomas in patients with tuberous sclerosis complex.

INTRODUCTION

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by multisystem hamartomas, including retinal astrocytic hamartomas (RAHs), which are a key diagnostic criterion. This study evaluates the en face swept-source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA) features of TSC-associated RAHs.

METHODS

A retrospective analysis of 10 patients with TSC-associated RAHs was conducted using en face SS-OCT, SS-OCTA, and fundus photography. Structural and vascular features of the lesions were assessed based on these imaging modalities.

RESULTS

Of the 10 TSC patients, 21 RAH lesions (18 type 1, 1 type 2, 2 type 3) were completely scanned. En face SS-OCT revealed vitreous changes in 17 of the 21 RAH lesions, with clear visualization of vitreoretinal traction in 6 lesions. Type 1 RAHs appeared as isoreflective or mildly hyporeflective masses with disarrangement of retinal nerve fibers. Calcified components in type 2 or type 3 RAHs appeared differently on the en face choroid slab, with type 2 RAHs featuring closely arranged isoreflective vesicles, while type 3 RAHs appeared as sharply defined dark areas. On SS-OCTA, a dense vascular network with disorganization of the radial papillary capillaries was observed in almost all of the type 1 RAHs, with half of them exhibiting congestive intrinsic microvasculature. Feeder vessels were identified in only two type 1 lesions. Non-flow, moth-eaten cavities were characteristic of the calcified components of type 2 or type 3 RAHs. The tumor vascular density was positively correlated with tumor maximal thickness in type 1 RAHs ( = 0.037).

CONCLUSION

En face SS-OCT provided a good display of RAH-related vitreoretinal traction and tumor calcification, while SS-OCTA, by clearly visualizing intratumoral vascularity, may assist in detecting signs of progressive tumor growth in TSC-associated RAHs.